Acyl Coenzyme A Thioesterase 9 Traffics Mitochondrial Short Chain Fatty Acids Toward De Novo Lipogenesis And Glucose Production In The Liver

This study investigated how the liver processes fats and sugars, particularly in the context of fatty liver disease (NAFLD), which affects over 25% of people worldwide. The researchers focused on a specific enzyme called Acyl-CoA thioesterase 9 (Acot9) that helps control how the liver uses fatty acids for energy and storage.

The scientists found that Acot9 acts like a metabolic switch in liver cells, directing fatty acids toward two problematic pathways: creating new fat stores and producing excess glucose. When they studied patients with obesity and fatty liver disease, these individuals had higher levels of Acot9 compared to healthy controls. In laboratory experiments with mice, removing the Acot9 enzyme protected animals from weight gain, liver fat accumulation, and excessive glucose production when fed high-calorie diets.

The enzyme works specifically in the mitochondria (the cell's energy factories) where it processes short-chain fatty acids. By doing so, it pushes the liver's metabolism toward making more triglycerides (stored fat) and glucose, rather than using these fats for other cellular functions like protein modification or energy production through normal pathways.

These findings suggest that Acot9 represents a promising therapeutic target for treating fatty liver disease and related metabolic problems. In clinical practice, this research could eventually lead to new treatments that inhibit this enzyme, potentially helping patients reverse fatty liver disease and improve glucose control without requiring dramatic lifestyle changes alone.